Star Health, Caplin Point our technical analysis stock picks

Buy STAR HEALTH @ 446, Stop loss: 415, Target: 490. Timeframe 2-3 weeks.

• The minor weakness of the last 2-3 sessions seems to have reversed up sharply on Wednesday.
• We observe a formation of higher bottom reversal pattern at Rs 418.
• The stock price is in an attempt of moving above the hurdle of 200day EMA at Rs 448 levels.
• Volume has started to expand during upside breakout in the stock price and RSI shows positive indication. Buy CAPLIN POINT LAB. @ 2142, Stop loss : 2055, Target: 2350. Timeframe: 2-3 weeks.
• The stock price has been in a range bound action over the last few weeks.
• We observe minor bullish pattern like higher highs and lows within a broader range movement on the daily chart.
• Now, the stock price is placed at the edge of upside breakout of range movement around 2170 levels. · Volume and RSI patterns are indicating positive bias for the stock price ahead.

Buy CAPLIN POINT LAB. @ 2142, Stop loss: 2055, Target: 2350. Timeframe 2-3 weeks

• The stock price has been in a range bound action over the last few weeks.
• We observe minor bullish pattern like higher highs and lows within a broader range movement on the daily chart.
• Now, the stock price is placed at the edge of upside breakout of range movement around 2170 levels. · Volume and RSI patterns are indicating positive bias for the stock price ahead.

Disclosure & Disclaimer

Disclosure:

I, Nagaraj S Shetti, (Graduation – BA), authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. SEBI conducted the inspection and based on their observations have issued advise/warning. The said observations have been complied with. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does have/does not have any material conflict of interest.

Any holding in stock – NO

For detailed disclaimers & disclosures please refer to https://www.hdfcsec.com/research-analyst-disclosure-and-disclaimer